10x Genomics Share Price (NASDAQ: TXG)

$13.13

▲

-0.28

(-2.09%)

Live

Last updated on August 20, 2025 at 11:36 PM IST

$₹

Check the interactive 10x Genomics Stock chart to analyse performance

10x Genomics stock performance

as on August 20, 2025 at 11:36 PM IST

Today's Low:$12.95
Today's High:$13.38
$13.13
1.37%
Downside
Day's Volatility :3.21%
Upside
1.87%
52 Weeks Low:$6.78
52 Weeks High:$24.76
$13.13
48.36%
Downside
52 Weeks Volatility :72.62%
Upside
46.97%

10x Genomics Stock Returns

Period	10x Genomics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	61.48%	1.5%	0.0%
6 Months	11.03%	-7.1%	0.0%
1 Year	-40.39%	-11.4%	0.0%
3 Years	-61.63%	2.9%	-9.6%

10x Genomics Inc Key Stats

Check 10x Genomics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$13.41
Open	$13.46
Today's High	$13.38
Today's Low	$12.95
Market Capitalization	$1.7B
Today's Volume	$2.8M
52 Week High	$24.76
52 Week Low	$6.78
Revenue TTM	$644.5M
EBITDA	$-110.9M
Earnings Per Share (EPS)	$-0.7
Profit Margin	-13.13%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-11.3%

Stock Returns calculator for 10x Genomics Stock including INR - Dollar returns

The 10x Genomics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

10x Genomics investment value today

Current value as on today

₹62,141

Returns

₹37,859

(-37.86%)

Returns from 10x Genomics Stock

₹41,748 (-41.75%)

Dollar Returns*

₹3,889 (+3.89%)

Indian investors sentiment towards 10x Genomics Stock

35%

Period: Jul 20, 2025 to Aug 19, 2025. Change in 30 Days versus previous period

Search interest for 10x Genomics Stock from India on INDmoney has increased by 35% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in 10x Genomics Inc

Name
Holdings %
Name
Holdings %
ARK Investment Management LLC
11.16%
Vanguard Group Inc
9.99%
FMR Inc
7.95%
BlackRock Inc
5.36%
Sumitomo Mitsui Trust Group Inc
4.83%
Millennium Management LLC
4.32%

Analyst Recommendation on 10x Genomics Stock

Rating

Trend

Buy

75%Buy

20%Hold

5%Sell

Based on 20 Wall street analysts offering stock ratings for 10x Genomics(by analysts ranked 0 to 5 stars)

10x Genomics Share Price Target

What analysts predicted

Upside of 14.83%

Target:

$15.08

Current:

$13.13

10x Genomics share price target is $15.08, a slight Upside of 14.83% compared to current price of $13.13 as per analysts' prediction.

10x Genomics Stock Insights

Price Movement
In the last 3 months, TXG stock has moved up by 48.0%
Increasing Revenue
Revenue is up for the last 2 quarters, 154.88M → 172.90M (in $), with an average increase of 10.4% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -49.02M → 34.53M (in $), with an average increase of 121.1% per quarter
TXG vs DOCS (1 yr)
In the last 1 year, Doximity, Inc. has given 75.4% return, outperforming this stock by 115.8%
TXG vs DOCS (3 yr)
In the last 3 years, Doximity, Inc. has given 92.5% return, outperforming this stock by 155.5%
Price to Sales
ForTXG every $1 of sales, investors are willing to pay $2.5, whereas for Doximity, Inc., the investors are paying $20.2 for every $1 of sales.

10x Genomics Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$245.9M	↑ 68.06%
Net Income	$-31.3M	↓ 72.22%
Net Profit Margin	-12.71%	↑ 64.17%

	FY20	Y/Y Change
Revenue	$298.8M	↑ 21.53%
Net Income	$-542.7M	↑ 1636.68%
Net Profit Margin	-181.61%	↓ 168.9%

	FY21	Y/Y Change
Revenue	$490.5M	↑ 64.13%
Net Income	$-58.2M	↓ 89.27%
Net Profit Margin	-11.87%	↑ 169.74%

	FY22	Y/Y Change
Revenue	$516.4M	↑ 5.28%
Net Income	$-166.0M	↑ 185.11%
Net Profit Margin	-32.15%	↓ 20.28%

	FY23	Y/Y Change
Revenue	$618.7M	↑ 19.81%
Net Income	$-255.1M	↑ 53.67%
Net Profit Margin	-41.23%	↓ 9.08%

	FY24	Y/Y Change
Revenue	$610.8M	↓ 1.28%
Net Income	$-182.6M	↓ 28.41%
Net Profit Margin	-29.9%	↑ 11.33%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$141.0M	↓ 23.36%
Net Income	$-59.9M	↑ 22.46%
Net Profit Margin	-42.52%	↓ 15.91%

	Q2 FY24	Q/Q Change
Revenue	$153.1M	↑ 8.58%
Net Income	$-37.9M	↓ 36.78%
Net Profit Margin	-24.75%	↑ 17.77%

	Q3 FY24	Q/Q Change
Revenue	$151.7M	↓ 0.95%
Net Income	$-35.8M	↓ 5.66%
Net Profit Margin	-23.58%	↑ 1.17%

	Q4 FY24	Q/Q Change
Revenue	$165.0M	↑ 8.81%
Net Income	$-49.0M	↑ 37.13%
Net Profit Margin	-29.71%	↓ 6.13%

	Q1 FY25	Q/Q Change
Revenue	$154.9M	↓ 6.14%
Net Income	$-34.4M	↓ 29.92%
Net Profit Margin	-22.18%	↑ 7.53%

	Q2 FY25	Q/Q Change
Revenue	$172.9M	↑ 11.64%
Net Income	$34.5M	↓ 200.52%
Net Profit Margin	19.97%	↑ 42.15%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$184.9M	↑ 57.12%

	FY20	Y/Y Change
Profit	$240.4M	↑ 30.03%

	FY21	Y/Y Change
Profit	$416.4M	↑ 73.23%

	FY22	Y/Y Change
Profit	$396.0M	↓ 4.89%

	FY23	Y/Y Change
Profit	$409.3M	↑ 3.36%

	FY24	Y/Y Change
Profit	$414.5M	↑ 1.26%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$95.6M	↓ 9.9%

	Q2 FY24	Q/Q Change
Profit	$106.9M	↑ 11.85%

	Q3 FY24	Q/Q Change
Profit	$106.4M	↓ 0.47%

	Q4 FY24	Q/Q Change
Profit	$111.0M	↑ 4.29%

	Q1 FY25	Q/Q Change
Profit	$105.4M	↓ 4.97%

	Q2 FY25	Q/Q Change
Profit	$125.1M	↑ 18.62%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$34.6M	↓ 145.32%
Investing Cash Flow	$-42.8M	↑ 537.46%
Financing Cash Flow	$414.6M	↑ 293.47%

	FY20	Y/Y Change
Operating Cash Flow	$-217.9M	↓ 729.27%
Investing Cash Flow	$-38.4M	↓ 10.23%
Financing Cash Flow	$468.9M	↑ 13.1%

	FY21	Y/Y Change
Operating Cash Flow	$-21.4M	↓ 90.19%
Investing Cash Flow	$-106.7M	↑ 177.98%
Financing Cash Flow	$35.3M	↓ 92.47%

	FY22	Y/Y Change
Operating Cash Flow	$-33.6M	↑ 57.24%
Investing Cash Flow	$-350.9M	↑ 228.76%
Financing Cash Flow	$15.8M	↓ 55.19%

	FY23	Y/Y Change
Operating Cash Flow	$-15.2M	↓ 54.78%
Investing Cash Flow	$133.5M	↓ 138.04%
Financing Cash Flow	$13.7M	↓ 13.58%

	FY24	Y/Y Change
Operating Cash Flow	$6.7M	↓ 143.85%
Investing Cash Flow	$-32.6M	↓ 124.44%
Financing Cash Flow	$10.9M	↓ 20.16%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-15.7M	↓ 161.05%
Investing Cash Flow	$10.6M	↓ 18.83%
Financing Cash Flow	$1.6M	↓ 70.82%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$7.5M	↓ 147.67%
Investing Cash Flow	$11.9M	↑ 12.37%
Financing Cash Flow	$4.6M	↑ 181.01%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$21.6M	↑ 188.7%
Investing Cash Flow	$-3.6M	↓ 130.28%
Financing Cash Flow	$156.0K	↓ 96.61%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-6.7M	↓ 131.18%
Investing Cash Flow	$-51.6M	↑ 1325.98%
Financing Cash Flow	$4.5M	↑ 2795.51%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$34.4M	↓ 609.05%
Investing Cash Flow	$-1.9M	↓ 96.33%
Financing Cash Flow	$422.0K	↓ 90.66%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$17.7M	↓ 48.45%
Investing Cash Flow	$-939.0K	↓ 50.4%
Financing Cash Flow	$3.5M	↑ 734.6%

10x Genomics Technicals Summary

Sell

Neutral

Buy

10x Genomics is currently in a neutral trading position according to technical analysis indicators.

10x Genomics Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
10x Genomics Inc	16.42%	11.03%	-40.39%	-61.63%	-87.75%
Tempus Ai	25.89%	-14.79%	24.39%	81.44%	81.44%
Doximity, Inc.	5.49%	-17.11%	75.43%	94.37%	19.92%
Ge Healthcare Technologies Inc.	-0.26%	-20.06%	-11.88%	22.28%	22.28%
Veeva Systems Inc.	1.15%	24.01%	46.75%	32.76%	6.47%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
10x Genomics Inc	NA	NA	NA	0.09	-0.11	-0.09	NA	6.21
Tempus Ai	30.86	30.86	NA	-0.78	-0.98	-0.12	NA	1.78
Doximity, Inc.	56.35	56.35	2.42	1.31	0.24	0.13	NA	5.47
Ge Healthcare Technologies Inc.	14.99	14.99	3.42	4.51	0.26	0.06	0.0	21.27
Veeva Systems Inc.	59.58	59.58	1.52	6.45	0.14	0.07	NA	38.11

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
10x Genomics Inc	Buy	$1.7B	-87.75%	NA	-13.13%
Tempus Ai	NA	$11.5B	81.44%	30.86	-20.98%
Doximity, Inc.	Hold	$12.3B	19.92%	56.35	39.88%
Ge Healthcare Technologies Inc.	Buy	$33.4B	22.28%	14.99	11.22%
Veeva Systems Inc.	Buy	$45.9B	6.47%	59.58	27.34%

10x Genomics Dividend announcements

10x Genomics Earnings
10x Genomics’s price-to-earnings ratio stands at None

About 10x Genomics Inc

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides; and Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Organization	10x Genomics
Employees	1306
CEO	Dr. Serge Saxonov Ph.D.
Industry	Commercial Services

Key Management of 10x Genomics Inc

Name	Title
Dr. Serge Saxonov Ph.D.	Co-Founder, CEO & Director
Dr. Benjamin J. Hindson Ph.D.	Co-Founder, President, Chief Scientific Officer & Director
Mr. Adam S. Taich	CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer
Mr. Eric S. Whitaker Esq.	Chief Legal Officer
Mr. Jim Goodrich	Chief of Global Operations
Mr. Michael Schnall-Levin	Founding Scientist & CTO
Ms. Cassie Corneau	Manager of Investor Relations & Strategic Finance
Ms. Mennah Moustafa	Chief Commercial Officer
Mr. Jens Durruthy	Associate Director of Product Management

Important FAQs about investing in TXG Stock from India :

What is 10x Genomics share price today?

10x Genomics share price today is $13.13 as on August 20, 2025 at 11:36 PM IST. 10x Genomics share today touched a day high of $13.38 and a low of $12.95.

What is the 52 week high and 52 week low for 10x Genomics share?

10x Genomics share touched a 52 week high of $24.76 and a 52 week low of $6.78. 10x Genomics stock price today i.e. August 20, 2025 at 11:36 PM IST is trending at $13.13, lower by 46.97% versus the 52 week high.

How to invest in 10x Genomics Stock (TXG) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for 10x Genomics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in 10x Genomics Shares that will get you 0.1142 shares as per 10x Genomics share price of $13.13 per share as on August 20, 2025 at 11:36 PM IST.

What is the minimum amount required to buy 10x Genomics Stock (TXG) from India?

Indian investors can start investing in 10x Genomics (TXG) shares with as little as ₹87.0225 or $1 (as of August 20, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹870.22 in 10x Genomics stock (as per the Rupee-Dollar exchange rate as on August 20, 2025). Based on 10x Genomics share’s latest price of $13.13 as on August 20, 2025 at 11:36 PM IST, you will get 0.7616 shares of 10x Genomics. Learn more about fractional shares .

What are the returns that 10x Genomics has given to Indian investors in the last 5 years?

10x Genomics stock has given -87.75% share price returns and 16.26% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?